Highlights from ASCO 2021
Highlights from ASCO 2021
Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma
ASCO 2021: Latest on PARPi and other treatments for mCRPC
ASCO 2021: Renal cancer roundup
Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations
OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021
UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients with EGFRm NSCLC with uncommon mutations
Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours
Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients with RAS-addicted solid cancers
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world